Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer

Autor Gridelli, Cesare, Felip, Enriqueta
Vydáno 2011

EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population

Autor Gridelli, Cesare, Rossi, Antonio
Vydáno 2012

A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting

Autor Gridelli, Cesare, Losanno, Tania
Vydáno v J Thorac Dis (2016)

The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?

Autor Troncone, Giancarlo, Gridelli, Cesare
Vydáno v Transl Lung Cancer Res (2017)

“Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer”: is there a substantial difference or not?

Autor Spagnuolo, Alessia, Gridelli, Cesare
Vydáno v J Thorac Dis (2018)

Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?

Autor Casaluce, Francesca, Gridelli, Cesare
Vydáno v Transl Lung Cancer Res (2018)

The combination strategies will be ready the right first-line choice for squamous lung cancer patients?

Autor Gridelli, Cesare, Casaluce, Francesca
Vydáno v Transl Lung Cancer Res (2018)

Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?

Autor Gridelli, Cesare, Sgambato, Assunta
Vydáno v Ann Transl Med (2019)

The adjuvant regimen for resected EGFR mutated patients: the “same-for-all-therapy” or not?

Autor Gridelli, Cesare, Casaluce, Francesca
Vydáno v Ann Transl Med (2020)

Narrative review of lung cancer treatment at the time of COVID-19 pandemia: pitfall and issues

Autor Casaluce, Francesca, Gridelli, Cesare
Vydáno v Transl Lung Cancer Res (2021)

Management of lung cancer in older people

Autor Gridelli, Cesare., Audisio, Riccardo A.
Vydáno 2013

The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives

Autor Rocco, Danilo, Gravara, Luigi D., Gridelli, Cesare
Vydáno v Curr Clin Pharmacol (2020)

Lung cancer resection in octogenarian patients

Autor Spaggiari, Lorenzo, Petrella, Francesco, Maione, Paolo, Gridelli, Cesare
Vydáno v J Thorac Dis (2018)

Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance

Autor Passarelli, Anna, Aieta, Michele, Sgambato, Alessandro, Gridelli, Cesare
Vydáno v Front Immunol (2020)

Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT)

Autor Normanno, Nicola, Barberis, Massimo, De Marinis, Filippo, Gridelli, Cesare
Vydáno v Cancers (Basel) (2020)

Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that’s the question

Autor Gridelli, Cesare, Casaluce, Francesca, Sgambato, Assunta, Monaco, Fabio, Guida, Cesare
Vydáno v Transl Lung Cancer Res (2016)

The role of pembrolizumab in the treatment of advanced non-small cell lung cancer

Autor Santabarbara, Giuseppe, Maione, Paolo, Rossi, Antonio, Palazzolo, Giovanni, Gridelli, Cesare
Vydáno v Ann Transl Med (2016)

J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?

Autor Gridelli, Cesare, Casaluce, Francesca, Sgambato, Assunta, Palazzolo, Giovanni, Maione, Paolo
Vydáno v J Thorac Dis (2018)

Lung cancer, elderly and immune checkpoint inhibitors

Autor Casaluce, Francesca, Sgambato, Assunta, Maione, Paolo, Spagnuolo, Alessia, Gridelli, Cesare
Vydáno v J Thorac Dis (2018)

The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era

Autor Spagnuolo, Alessia, Muto, Matteo, Monaco, Fabio, Colantuoni, Giuseppe, Gridelli, Cesare
Vydáno v Transl Lung Cancer Res (2019)